Prognostic significance of constitutive phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase phosphorylation in acute myeloid leukemia

References

• Rowe JM. Clinical progress in acute myeloid leukemia. Best Pract Res Clin Haematol 2008;21:597–599.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC; 2008.
   Google Scholar
• Dohner K, Dohner H. Molecular characterization of acute myeloid leukemia. Haematologica 2008;93:976–982.
   PubMed Web of Science ®Google Scholar
• Mrozek K, Dohner H, Bloomfield CD. Influence of new molecular prognostic markers in patients with karyotypically normal acute myeloid leukemia: recent advances. Curr Opin Hematol 2007; 14:106–114.
   PubMed Web of Science ®Google Scholar
• Schlenk RF, Dohner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Eng J Med 2008;358:1909–1918.
   PubMed Web of Science ®Google Scholar
• Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001;98:1752–1759.
   PubMed Web of Science ®Google Scholar
• Frohling S, Schlenk RF, Breitruck J, et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics. Blood 2002;100:4372–4380.
   PubMed Web of Science ®Google Scholar
• Whitman SP, Archer KJ, Feng L, et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res 2001;61:7233–7239.
   PubMed Web of Science ®Google Scholar
• Thiede C, Steudel C, Mohr B, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous w association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002;99:4326–4335.
   PubMed Web of Science ®Google Scholar
• Gale RE, Green C, Allen C, et al. The impact of FLT3 internal tandem duplication mutant level, number, size and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 2008;111:2776–2784.
   PubMed Web of Science ®Google Scholar
• Paschka P, Marcucci G, Ruppert AS, et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol 2006;24:3904–3911.
   PubMed Web of Science ®Google Scholar
• Cairoli R, Beghini A, Grillo G, et al. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood 2006;107:3463–3468.
   PubMed Web of Science ®Google Scholar
• Schnittiger S, Kohl TM, Haferlach T, et al. KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood 2006;107:1791–1799.
   PubMed Web of Science ®Google Scholar
• Verhaak RG, Goudswaard CS, van Putten W, et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML):association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood 2005;106:3747–3754.
   PubMed Web of Science ®Google Scholar
• Dohner K, Schlenk RF, Habdank M, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics:interaction with other gene mutations. Blood 2005;106:3740–3746.
   PubMed Web of Science ®Google Scholar
• Dufour A, Schneider F, Metzeler KH, et al. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype respresents a distinct genetic entity associated with a favorable clinical outcome. J Clin Oncol 2010;28:570–577.
   PubMed Web of Science ®Google Scholar
• Wouters BJ, Lowenberg B, Erpelinck-Verschueren CA, et al. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favourable outcome. Blood 2009;113:3088–3091.
   PubMed Web of Science ®Google Scholar
• Pabst T, Eyholzer M, Fos J, et al. Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis. Br J Cancer 2009;100:1343–1346.
   PubMed Web of Science ®Google Scholar
• Renneville A, Boissel N, Gachard N, et al. The favorable impact of CEBPA mutations in patients with acute myeloid leukemia is only observed in the absence of associated cytogenetic abnormalities and FLT3 internal tandem duplication. Blood 2009;113:5090–5093.
   PubMed Web of Science ®Google Scholar
• Gallay N, Dos Santos C, Cuzin L, et al. The level of AKT phosphorylation on threonine 308 but not on serine 473 is associated with high-risk cytogenetics and predicts poor overall survival in acute myeloid leukemia. Leukemia 2009;23:1029–1038.
   PubMed Web of Science ®Google Scholar
• Min YH, Eom JI, Cheong JW, et al. Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia:its significance as a prognostic variable. Leukemia 2003;17:995–997.
   PubMed Web of Science ®Google Scholar
• Tamburini J, Elie C, Bardet V, et al. Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients. Blood 2007;110: 1025–1028.
   PubMed Web of Science ®Google Scholar
• Sholl C, Gilliland DG, Frohling S. Deregulation of signaling pathways in acute myeloid leukemia. Semin Oncol 2008;35: 336–345.
   PubMed Web of Science ®Google Scholar
• Steelman LS, Abrams SL, Whelan J, et al. Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia 2008;22:686–707.
   PubMed Web of Science ®Google Scholar
• Towatari M, Iida H, Tanimoto M, et al. Constitutive activation of mitogen-activated protein kinase pathway in acute leukemia cells. Leukemia 1997;11:479–484.
   PubMed Web of Science ®Google Scholar
• McCubrey JA, Steelman LS, Kempf CR, et al. Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. J Cell Physiol 2011;226:2762–2781.
   PubMed Web of Science ®Google Scholar
• McCubrey JA, Steelman LS, Chappell WH, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007;1773:1263–1284.
   PubMed Web of Science ®Google Scholar
• McCubrey JA, Steelman LS, Abrams SL, et al. Targeting survival cascades induced by activation of Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy. Leukemia 2008;22:708–722.
   PubMed Web of Science ®Google Scholar
• Hamda H, Tsuruo T. Putification of the 170- to 180-kilodalton membrane glycoprotein associated with multidrug resistance- 170- to 180-kilodalton membrane protein is an ATPase. J Biol Chem 1998;263:1454–1458.
   Google Scholar
• Cordon-Cardo C, O’Brien JP, Casalas D, et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 1989;86:695–698.
   PubMed Web of Science ®Google Scholar
• Thiebaut F, Tsuruo T, Hamada H, et al. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987;84:7735–7738.
   PubMed Web of Science ®Google Scholar
• Chaudhary PM, Mechetner EB, Roninson IB. Expression and activity of the multidrug-resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 1992;80:2735–2739.
   PubMed Web of Science ®Google Scholar
• Chaudhary PM, Roninson IB. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 1991;66:85–94.
   PubMed Web of Science ®Google Scholar
• Arceci RJ, Croop JM, Horowitz SB, et al. The gene encoding multidrug resistance is induced and expressed at high levels during pregnancy in the secretory epithelium of the uterus. Proc Natl Acad Sci USA 1988;85:4350–4354.
   PubMed Web of Science ®Google Scholar
• Hamada H, Tsuruo T. Characterization of the ATPase activity of the Mr 170,000 to 180,000 membrane glycoprotein (P-glycoprotein) associated with multidrug resistance in K562/ADM cells. Cancer Res 1988;48:4926–4932.
   PubMed Web of Science ®Google Scholar
• Ueda K, Cardarelli C, Gottesman MM, et al. Expression of a full-length cDNA for the human “MDR1” gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci USA 1987;84:3004–3008.
   PubMed Web of Science ®Google Scholar
• Horowitz SB, Cohen D, Rao S, et al. Taxol: mechanisms of action and resistance. J Natl Cancer Inst Monogr 1993;15:55–61.
   PubMedGoogle Scholar
• Borg AG, Burgess R, Green LM, et al. Overexpression of lung-resistance protein and increased P-gp function in acute myeloid leukemia cells predict a poor response to chemotherapy and reduced patient survival. Br J Haematol 1998;103:1083–1091.
   PubMed Web of Science ®Google Scholar
• Nussler V, Pelka-Fleischer R, Zwierzina H, et al. P-glycoprotein expression in patient with acute leukemia – clinical relevance. Leukemia 1996;10(Suppl. 3):S23–S31.
   PubMed Web of Science ®Google Scholar
• Zhou DC, Zittoun R, Marie JP. Expression of multidrug resistance associated protein (MRP) and multidrug resistance (MDR1) genes in acute myeloid leukemia. Leukemia 1995;9:1661–1666.
   PubMed Web of Science ®Google Scholar
• Tazzari PL, Capellini A, Ricci F, et al. Multidrug resistance-associated protein 1 expression is under the control of phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts. Leukemia 2007;21:427–438.
   PubMed Web of Science ®Google Scholar
• Willemze R, Suciu S, Meloni G, et al. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial. J Clin Oncol 2014;32:219–228.
   PubMed Web of Science ®Google Scholar
• Adès L, Chevret S, Raffoux E, et al.; European APL group. Long-term follow-up of European APL 2000 trial, evaluating the role of cytarabine combined with ATRA and daunorubicin in the treatment of nonelderly APL patients. Am J Hematol 2013;88:556–559.
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Kreutzmann H, Straif K, et al. High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in w acute myeloid leukemia. Blood 1987;69:744–749.
   PubMed Web of Science ®Google Scholar
• Huet S, Marie JP, Gualde N, et al. Reference method for detection of Pgp mediated multidrug resistance in human hematological malignancies: a method validated by laboratories of the French Drug Resistance Network. Cytometry 1998;34:248–256.
   PubMedGoogle Scholar
• Petriz J, Garcia-Lopez J. Flow cytometric analysis of P-glycoprotein function using Rhodamine 123. Leukemia 1997;11: 1124–1130.
   PubMed Web of Science ®Google Scholar
• Available from: www.bdbiosciences.com/documents/Phosflow_Protocol_for_Human_PBMCs.pdf
   Google Scholar
• Krutzik PO, Nolan GP. Intracellular phospho-protein staining techniques for flow cytometry: monitoring single cell signaling events. Cytometry A 2003;55:61–70.
   PubMed Web of Science ®Google Scholar
• Krutzik PO, Irish JM, Nolan GP, et al. Analysis of protein phosphorylation and cellular signaling events by flow cytometry: techniques and clinical applications. Clin Immunol 2004;110: 206–221.
   PubMed Web of Science ®Google Scholar
• Bardet V, Tamburini J, Ifrah N, et al. Single cell analysis of phosphoinositide 3-kinase/Akt and ERK activation in acute myeloid leukemia by flow cytometry. Haematologica 2006;91: 757–764.
   PubMed Web of Science ®Google Scholar
• Seabright M. A rapid banding technique for human chromosomes. Lancet 1971;2:971–972.
   PubMed Web of Science ®Google Scholar
• Gozzeti A, Le Beau MM. Fluorescence in situ hybridizations: uses and limitations. Semin Hematol 2000;37:320–333.
   PubMed Web of Science ®Google Scholar
• Schaffer LG, Slovak ML, Campbell LJ. ISCN 2009: an international system for human cytogenetic nomenclature: recommendations of the International Standing Committee on Human Cytogenetic Nomenclature. Basel: Karger Medical Scientific; 2009.
   Google Scholar
• Nakao M, Yokota S, Iwai T, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 1996;10: 1911–1918.
   PubMed Web of Science ®Google Scholar
• Hoeing JM, Heisey DM. The abuse of power: the pervasive fallacy of power calculations for data analysis. Am Stat 2001;55:1–6.
   Web of Science ®Google Scholar
• Broxterman HJ, Sonneveld P, van Putten WJ, et al. P-glycoprotein in primary acute myeloid leukemia and treatment outcome of idarubicin/cytosine arabinoside-based induction therapy. Leukemia 2000;14:1018–1024.
   PubMed Web of Science ®Google Scholar
• Park S, Park CH, Hahm ER, et al. Activation of Raf1 and the ERK pathway in response to L-ascorbic acid in acute myeloid leukemia cells. Cell Signal 2005;17:111–119.
   PubMed Web of Science ®Google Scholar
• Fang Y, Zhong L, Lin M, et al. MEK/ERK dependent activation of STAT1 mediates dasatinib-induced differentiation of acute myeloid leukemia. PLoS One 2013;8:e66915.
   PubMed Web of Science ®Google Scholar
• Svensson S, Jirstrom K, Ryden L, et al. ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis. Oncogene 2005;24: 4370–4379.
   PubMed Web of Science ®Google Scholar
• Deschenes-Simard X, Gaumont-Leclerc MF, Bourdeau V, et al. Tumor suppressor activity of the ERK/MAPK pathway by promoting selective protein degradation. Genes Dev 2013;27:900–915.
   PubMed Web of Science ®Google Scholar
• Ranganathan AC, Adam AP, Aguirre-Ghiso JA. Opposing roles of mitogenic and stress signaling pathways in the induction of cancer dormancy. Cell Cycle 2006;5:1799–1807.
   PubMed Web of Science ®Google Scholar
• Lin JC, Chang SY, Hsien DS, et al. Modulation of mitogen-activated protein kinase cascades by differentiation-1 protein: acquired drug resistance of hormone independent prostate cancer cells. J Urol 2005;174:2022–2026.
   PubMed Web of Science ®Google Scholar
• Koul HK, Pal M, Koul S. Role of p38 MAP kinase signal transduction in solid tumors. Genes Cancer 2013;4:342–359.
   PubMedGoogle Scholar
• Bulavin DV, Fornace AJ Jr. P38 MAP kinase's emerging role as a tumor suppressor. Adv Cancer Res 2004;92:95–118.
   PubMed Web of Science ®Google Scholar